ACP Updates Recommendations for Oral Medications in T2DM

Share this content:
ACP Updates Recommendations for Oral Medications in T2DM
ACP Updates Recommendations for Oral Medications in T2DM

TUESDAY, Jan. 3, 2017 (HealthDay News) -- The American College of Physicians (ACP) has updated recommendations on the oral pharmacologic treatment of type 2 diabetes in adults. The clinical practice guideline update was published online Jan. 3 in the Annals of Internal Medicine.

Amir Qaseem, M.D., Ph.D., from the ACP in Philadelphia, and colleagues developed guidelines relating to oral pharmacologic treatment of type 2 diabetes in adults. They conducted a systematic review of randomized controlled trials and observational studies on the comparative effectiveness of oral medications for type 2 diabetes. The interventions assessed included metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

The ACP recommends that clinicians prescribe metformin when pharmacologic therapy is needed to improve glycemic control (strong recommendation; moderate-quality evidence). When a second oral therapy is considered in order to improve glycemic control, clinicians should consider adding a sulfonylurea, thiazolidinedione, SLGT-2 inhibitor, or a DPP-4 inhibitor to metformin (weak recommendation; moderate-quality evidence). After discussing benefits, adverse effects, and costs, clinicians and patients should select among medications.

"The ACP developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults," the authors write. "This guideline serves as an update to the 2012 ACP guideline on the same topic."

One author disclosed financial ties to Informed Medical Decisions Foundation and Healthwise, both nonprofits.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »